MRK Merck & Company Inc.

Biotech Analyst Ratings

Latest News

1. 10 May 2022 Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)

   Data from studies of six medicines and pipeline candidates in more than 25 cancers to be presented

   Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 3-7. Presentations will feature new or updated findings from Merck's broad portfolio of cancer medicines: KEYTRUDA; WELIREG™ (belzutifan); LYNPARZA^® (olaparib, in collaboration with AstraZeneca); and LENVIMA^® (lenvatinib, in collaboration with Eisai). Additionally, Merck will present data from its diverse pipeline of immuno-therapeutic candidates, including the…

   View Full Article
2. 05 May 2022 Organon Reports Results for the First Quarter Ended March 31, 2022

   • First quarter 2022 revenue of $1,567 million
   • Net income from continuing operations of $348 million, or $1.36 per diluted share; Adjusted net income from continuing operations of $420 million, or $1.65 per diluted share
   • Adjusted EBITDA of $647 million
   • Board of Directors declares quarterly dividend of $0.28 per share
   • Full year 2022 financial guidance ranges affirmed

   Organon (NYSE:OGN) (the "company"), today announced its results for the first quarter ended March 31, 2022.

   "The first quarter marked a solid start to the year. We continued to expand our Women's Health offerings by acquiring the rights to Marvelon™ (ethinylestradiol, desogestrel) and Mercilon™ (ethinylestradiol, desogestrel) in certain markets, as well as by entering…

   View Full Article
3. 04 May 2022 Merck to Participate in Bank of America Securities 2022 Healthcare Conference

   Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Executive Vice President and Chief Financial Officer Caroline Litchfield will participate in a fireside chat at the live Bank of America Securities 2022 Healthcare Conference.

   The conversation will take place Wednesday, May 11, at 11:40 a.m. ET. Investors, analysts, members of the media and the general public are invited to listen at https://bofa.veracast.com/webcasts/bofa/hc2022/idrK4v7a.cfm.

   About Merck

   For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives…

   View Full Article
4. 29 April 2022 European Commission Approves Merck's KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer

   KEYTRUDA is the First Immunotherapy to be Approved for Patients with MSI-H/dMMR Biomarkers in Five Different Types of Cancer in Europe

   Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine-based combination therapy; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation…

   View Full Article
5. 29 April 2022 European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)

   First Immunotherapy-Based Regimen Approved in Europe for These Patients With Persistent, Recurrent or Metastatic Cervical Cancer

   Approval Based on Overall Survival Benefit Demonstrated in Phase 3 KEYNOTE-826 Trial

   Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck's anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1). This approval is based on results from the Phase 3 KEYNOTE-826 trial, in which KEYTRUDA plus chemotherapy with or without bevacizumab (the KEYTRUDA regimen) demonstrated…

   View Full Article